In order to determine whether we can increase antitumor efficacy of VV by IL-36γ, we constructed three IL-36γ-armed VVs, namely vvTK-IL-36γ, vvDD-IL-36γ, and vvTD-IL-36γ, by inserting an active form of IL-36γ into three VV backbones with different tumor selectivity and oncolytic activities (Fig. 1a). This evidence concerns the gene IL36G and neoplasm.